Upper GI pharm Flashcards
misoprostol site of action
prostaglandin analog –> epithlial cell (mucus and bicarb), parietal cell (blocks cAMP –> blocked H secretion)
PPIs
omeprazole (prilosec), Lansoprazole (prevacid)
PPI mechanism of action
prodrug –> activated by H in parietal cells –> trapped in acidic secretory canniliculi –> irreversible inactivation of H/K ATPase
PPI absorption
rapid, highly protein-bound. bioavailability improved with enteric coating or NaHCO3.
give 1 hour before meals
PPI metabolism
first pass = CYP450
no accumulation in chronic renal failure
Indications for PPI
GERD, PUD, NSAID-induced ulcers, prevention of stress gastritis in ICU, Zollinger-Ellison syndrome
ADRs of PPIs
usually mild
DDIs of PPIs
omaprazole may inhibit conversion of antiplatelet agent clopidogrel to active form
H2 receptor antagonists
Ranitidine (Zantac), Cimetidine (Tagamet), Famotidine (Pepcid), Nizatidine (Axid)
H2 blocker use
best for blocking NOCTURNAL acid secretion
GERD, PUD, stress-related gastritis
H2 blocker absorption
rapid
H2 blocker metabolism
some hepatic metabolism, but no dosage adjustment for liver disease
renal excretion (dosage reduction if ipaired renal function)
H2 blocker side effects
generally well-tolerated. dizziness, diarrhea, constipation, headache
cimetidine can lead to mental status change and/or endocrine changes (gynecomastia, galactorrhea, decreased sperm count)
H2 blocker DDIs
cimetidine inhibits P450; all antisecretory agents –> increased gastric pH –> decreased ketoconazole absorption
Sucralfate mechanism of action
binds necrotic ulcer tissueand forms protective barrier –> blocked hydrolysis of mucosal proteins by pepsin